Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGF1 | P05230 | 2/20 | 0.61 |
| ▸ | FGF2 | P09038 | 2/20 | 0.61 |
| ▸ | SERPINC1 | P01008 | 1/20 | 0.35 |
| ▸ | HPSE | Q9Y251 | 10/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperazine SCHEMBL28832657 | 0.94 | FGF1 (0.55) | FGF1FGF2SERPINC1HPSE | |
| Bicarbonate SCHEMBL27797481 | 0.93 | FGF1 (0.55) | FGF1FGF2SERPINC1HPSE | |
| Sucrosofate SCHEMBL145069 | 0.90 | FGF1 (0.74) | FGF1FGF2SERPINC1HPSE | |
| Sucrosofate SCHEMBL145070 | 0.90 | FGF1 (0.74) | FGF1FGF2SERPINC1HPSE | |
| Sucrosofate SCHEMBL18467935 | 0.90 | FGF1 (0.74) | FGF1FGF2SERPINC1HPSE | |
| Sucrosofate SCHEMBL16661861 | 0.90 | FGF1 (0.74) | FGF1FGF2SERPINC1HPSE | |
| Sucrosofate SCHEMBL16661862 | 0.90 | FGF1 (0.74) | FGF1FGF2SERPINC1HPSE | |
| Sucrosofate SCHEMBL921799 | 0.89 | FGF1 (0.72) | FGF1FGF2SERPINC1HPSE | |
| Sucrosofate SCHEMBL18742107 | 0.89 | FGF1 (0.72) | FGF1FGF2SERPINC1HPSE | |
| Sucrosofate SCHEMBL18244210 | 0.83 | FGF1 (0.65) | FGF1FGF2SERPINC1HPSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 13939 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075470-A | Application of oridonin in preparation of external preparation for treating skin scald | — | 2026-05-26 | — | — | CN | claimed |
| EP-4736862-A1 | COMPOSITION PROVIDING IMPROVED ORAL BIOAVAILABILITY OF DRUG AND METHOD THEREFOR | Hang Zhou Sciwind Biosciences Co., Ltd. (CN) | 2026-05-06 | — | — | EP | claimed |
| US-20260115161-A1 | 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN | LAMINAR PHARMACEUTICALS S A (ES) | 2026-04-30 | — | — | US | claimed |
| EP-4271360-B1 | NEW COMBINATIONS AND COMPOSITIONS OF SUCRALFATE IN ALGINATE AND THEIR USE IN THERAPY | NYUMA PHARMA SRL (IT) | 2026-04-29 | — | — | EP | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-12599622-B2 | Compounds to modulate intestinal absorption of nutrients | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2026-04-14 | — | — | US | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| EP-4684804-A1 | CONJUGATION PRODUCT COMPRISING AN ANTIGEN BINDING MOIETY AND A MUCIN BINDING MOIETY | Freie Universität Berlin (DE) | 2026-01-28 | — | — | EP | claimed |
| EP-4680203-A1 | COMPOSITIONS FOR SUSTAINED RELEASE OF POORLY SOLUBLE ACTIVE INGREDIENTS | Prolevi Bio AB (SE) | 2026-01-21 | — | — | EP | claimed |
| EP-4663187-A1 | 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN | Laminar Pharmaceuticals, S.A. (ES) | 2025-12-17 | — | — | EP | claimed |
| EP-0286978-A1 | Pharmaceutical compositions in the form of stable sucralfate suspensions free of suspending agents | LISAPHARMA SPA (IT) | 1988-10-19 | — | — | EP | claimed |
| EP-0109072-B1 | DIAGNOSTIC PROCEDURES USING RADIO LABELED SUCRALFATE AND DERIVATIVES OR PRECURSORS THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1988-08-10 | — | — | EP | claimed |
| EP-0245855-A2 | Sucralfate preparations for application on esophagus mucosa | Chugai Seiyaku Kabushiki Kaisha (JP) | 1987-11-19 | — | — | EP | claimed |
| US-4668665-A | STORAGE STABILITY, AMINO ACID, ADHESIVES, ANTIULCER | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1987-05-26 | — | — | US | claimed |
| CN-85109551-A | The preparation sucralfate suspension | — | 1987-05-20 | — | — | CN | claimed |
| EP-0107209-B1 | SUCRALFATE PREPARATION | Chugai Seiyaku Kabushiki Kaisha (JP) | 1986-09-24 | — | — | EP | claimed |
| EP-0167958-A2 | Oral solid pharmaceutical form with sequential action for the administering of drugs with ulcerogenic side effect | LABORATORIO ITALIANO BIOCHIMICO FARMACEUTICO LISAPHARMA S.P.A. (IT) | 1986-01-15 | — | — | EP | claimed |
| EP-0136100-A2 | Sucralfate suspension for use in treating ulcers | Marion Merrell Dow Inc. (US) | 1985-04-03 | — | — | EP | claimed |
| EP-0109072-A2 | Diagnostic procedures using radio labeled sucralfate and derivatives or precursors thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1984-05-23 | — | — | EP | claimed |
| EP-0107209-A1 | Sucralfate preparation | Chugai Seiyaku Kabushiki Kaisha (JP) | 1984-05-02 | — | — | EP | claimed |